Stelios Papadopoulos

Insider Reports History

Location
Alameda, CA
Signature
/s/ Jeffrey Rona, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Stelios Papadopoulos:

Form 4 holding Director

BIOGEN INC.

Security class
Common Stock
Shares / value
17,375
Estimated value
$4,309,000
Report date
15 Jun 2022
Price
$248.00
Ownership
Stelios Holdings, LLC
Form 4 holding Director

BIOGEN INC.

Security class
Common Stock
Shares / value
10,831
Estimated value
$2,686,088
Report date
15 Jun 2022
Price
$248.00
Ownership
Esperanza Holdings, LLC
Form 4 holding Director

BIOGEN INC.

Security class
Common Stock
Shares / value
10,095
Estimated value
$2,503,560
Report date
15 Jun 2022
Price
$248.00
Ownership
Direct
Form 4 holding Director

Ovid Therapeutics Inc.

Security class
Stock Option (right to buy)
Shares / value
90,000
Estimated value
Report date
03 Mar 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Ovid Therapeutics Inc.

Security class
Employee Stock Option (Right to Buy)
Shares / value
65,000
Estimated value
Report date
26 Feb 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

EXELIXIS, INC.

Security class
Option (right to buy)
Shares / value
0
Estimated value
Report date
15 May 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Stelios Papadopoulos

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .